- Home
- AUPH vs DFIN Comparison
AUPH vs DFIN Comparison
Compare AUPH & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- DFIN
- Stock Information
- Founded
- AUPH 1993
- DFIN 1983
- Country
- AUPH Canada
- DFIN United States
- Employees
- AUPH N/A
- DFIN N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- DFIN Other Consumer Services
- Sector
- AUPH Health Care
- DFIN Consumer Discretionary
- Exchange
- AUPH Nasdaq
- DFIN Nasdaq
- Market Cap
- AUPH 1.4B
- DFIN 1.6B
- IPO Year
- AUPH 1999
- DFIN N/A
- Fundamental
- Price
- AUPH $12.83
- DFIN $53.40
- Analyst Decision
- AUPH Strong Buy
- DFIN Strong Buy
- Analyst Count
- AUPH 3
- DFIN 3
- Target Price
- AUPH $12.00
- DFIN $68.67
- AVG Volume (30 Days)
- AUPH 1.5M
- DFIN 219.4K
- Earning Date
- AUPH 11-06-2025
- DFIN 10-30-2025
- Dividend Yield
- AUPH N/A
- DFIN N/A
- EPS Growth
- AUPH N/A
- DFIN N/A
- EPS
- AUPH 0.42
- DFIN 2.79
- Revenue
- AUPH $260,111,000.00
- DFIN $755,000,000.00
- Revenue This Year
- AUPH $16.92
- DFIN N/A
- Revenue Next Year
- AUPH $14.43
- DFIN $4.66
- P/E Ratio
- AUPH $29.12
- DFIN $19.17
- Revenue Growth
- AUPH 25.59
- DFIN N/A
- 52 Week Low
- AUPH $6.55
- DFIN $37.80
- 52 Week High
- AUPH $12.90
- DFIN $70.55
- Technical
- Relative Strength Index (RSI)
- AUPH 63.83
- DFIN 40.42
- Support Level
- AUPH $12.18
- DFIN $52.66
- Resistance Level
- AUPH $12.90
- DFIN $54.67
- Average True Range (ATR)
- AUPH 0.42
- DFIN 1.40
- MACD
- AUPH -0.06
- DFIN -0.20
- Stochastic Oscillator
- AUPH 92.89
- DFIN 15.50
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.